中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2014年
4期
100-105
,共6页
非小细胞肺癌%重组人血管内皮抑制素%分子生物学
非小細胞肺癌%重組人血管內皮抑製素%分子生物學
비소세포폐암%중조인혈관내피억제소%분자생물학
non-small cell lung cancer%recombinant human endostatin%molecular biology
目的：探讨分子生学标记物与重组人血管内皮抑制素靶向治疗非小细胞肺癌（non-small-cell lung cancer，NSCLC）疗效之间的关系。方法选择符合要求的非小细胞肺癌患者68例，随机均分为A组和B组，每组34例。A组采用多西他赛＋顺铂（docetaxel and cisplatin，DP）及吉非替尼化疗，B组在A组化疗方案的基础上加用重组人血管内皮抑制素。采用免疫组化的方法检测表皮生长因子受体（epidermao growth factor receptor，EGFR）、KRAS 基因（K-ras，p21）、血管内皮生长因子（vascular endothelial growthfactor，VEGF）、乳腺癌1号基因（breast cancer susceptibility gene 1，BRCA1）、棘皮动物微管相关类蛋白4与间变性淋巴瘤激酶融合基因（echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase，EML4-ALK）、核苷酸切除修复交叉互补1（excision repair cross complementing 1，ERCC1）、β-微管蛋白和分化抗原簇3（Cluster of differentiation 3，CD3）生物学标记物的表达情况。结合2组患者生物学标志物的表达情况和无进展生存期（progression free survival，PFS），统计出适合不同方案的人群类型。结果 B组的中位PFS较A组显著延长；无论VEGF和BRCA1低表达或高表达，B组的中位PFS较A组显著提高；ERCC1、KRAS、EML4-ALK和β-微管蛋白高表达，B组的中位PFS较A组有显著提高；EGFR和CD3低表达，B 组的中位 PFS 较 A 组显著延长（P＜0.05）。结论VEGF和BRCA1高表达或低表达，KRAS、ERCC1、EML4-ALK和β-微管蛋白高表达及EGFR和CD3低表达的非小细胞肺癌患者对DP及吉非替尼联合重组人血管内皮抑制素靶向治疗较为敏感。
目的：探討分子生學標記物與重組人血管內皮抑製素靶嚮治療非小細胞肺癌（non-small-cell lung cancer，NSCLC）療效之間的關繫。方法選擇符閤要求的非小細胞肺癌患者68例，隨機均分為A組和B組，每組34例。A組採用多西他賽＋順鉑（docetaxel and cisplatin，DP）及吉非替尼化療，B組在A組化療方案的基礎上加用重組人血管內皮抑製素。採用免疫組化的方法檢測錶皮生長因子受體（epidermao growth factor receptor，EGFR）、KRAS 基因（K-ras，p21）、血管內皮生長因子（vascular endothelial growthfactor，VEGF）、乳腺癌1號基因（breast cancer susceptibility gene 1，BRCA1）、棘皮動物微管相關類蛋白4與間變性淋巴瘤激酶融閤基因（echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase，EML4-ALK）、覈苷痠切除脩複交扠互補1（excision repair cross complementing 1，ERCC1）、β-微管蛋白和分化抗原簇3（Cluster of differentiation 3，CD3）生物學標記物的錶達情況。結閤2組患者生物學標誌物的錶達情況和無進展生存期（progression free survival，PFS），統計齣適閤不同方案的人群類型。結果 B組的中位PFS較A組顯著延長；無論VEGF和BRCA1低錶達或高錶達，B組的中位PFS較A組顯著提高；ERCC1、KRAS、EML4-ALK和β-微管蛋白高錶達，B組的中位PFS較A組有顯著提高；EGFR和CD3低錶達，B 組的中位 PFS 較 A 組顯著延長（P＜0.05）。結論VEGF和BRCA1高錶達或低錶達，KRAS、ERCC1、EML4-ALK和β-微管蛋白高錶達及EGFR和CD3低錶達的非小細胞肺癌患者對DP及吉非替尼聯閤重組人血管內皮抑製素靶嚮治療較為敏感。
목적：탐토분자생학표기물여중조인혈관내피억제소파향치료비소세포폐암（non-small-cell lung cancer，NSCLC）료효지간적관계。방법선택부합요구적비소세포폐암환자68례，수궤균분위A조화B조，매조34례。A조채용다서타새＋순박（docetaxel and cisplatin，DP）급길비체니화료，B조재A조화료방안적기출상가용중조인혈관내피억제소。채용면역조화적방법검측표피생장인자수체（epidermao growth factor receptor，EGFR）、KRAS 기인（K-ras，p21）、혈관내피생장인자（vascular endothelial growthfactor，VEGF）、유선암1호기인（breast cancer susceptibility gene 1，BRCA1）、극피동물미관상관류단백4여간변성림파류격매융합기인（echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase，EML4-ALK）、핵감산절제수복교차호보1（excision repair cross complementing 1，ERCC1）、β-미관단백화분화항원족3（Cluster of differentiation 3，CD3）생물학표기물적표체정황。결합2조환자생물학표지물적표체정황화무진전생존기（progression free survival，PFS），통계출괄합불동방안적인군류형。결과 B조적중위PFS교A조현저연장；무론VEGF화BRCA1저표체혹고표체，B조적중위PFS교A조현저제고；ERCC1、KRAS、EML4-ALK화β-미관단백고표체，B조적중위PFS교A조유현저제고；EGFR화CD3저표체，B 조적중위 PFS 교 A 조현저연장（P＜0.05）。결론VEGF화BRCA1고표체혹저표체，KRAS、ERCC1、EML4-ALK화β-미관단백고표체급EGFR화CD3저표체적비소세포폐암환자대DP급길비체니연합중조인혈관내피억제소파향치료교위민감。
Objective To investigate the relationship between molecular biological markers and recombinant human endostatin targeted therapy in non-small-cell lung cancer(NSCLC).Methods 68 cases patients with non-small-cell lung cancer to meet the requirements were randomly divided into group A (n=34)and group B (n=34).Group A received docetaxel and cisplatin(DP)and gefitinib;group B received recombinant human endostatin on the base of group A.The biological markers species,such as,EGFR,KRAS,VEGF,BRCA1,EML4-ALK,ERCC1,β-tubulin and CD3 were detected by immunohistochemical.The types of population for different programs were summarized according to the expression of biological markers and progression free survival (PFS)of the two groups. Results Group B median PFS was significantly longer than that in group A;no matter low or high expression of VEGF and BRCA1,group B median PFS was significantly longer than that in group A(P<0.05);high expression of ERCC1,KRAS,EML4-ALK andβ-tubulin,group B median PFS was significantly longer than that in group A(P<0.05);low expression of EGFR and CD3,group B median PFS was significantly longer than that in group A (P<0.05 ).Conclusion No matter low or high expression of VEGF and BRCA1 ,low expression of KRAS, ERCC1,EML4-ALK and β-tubulin and high expression of EGFR and CD3 in patients with non-small cell lung cancer may be more sensitive to the treatment of DP and gefitinib combined with recombinant human endostatin.
